Adenosine compounds useful in the prevention and treatment of vaccinia virus infections

ABSTRACT

Substituted 1-(benzyloxy)adenosines and the use of substituted 1-(benzyloxy)adenosines and adenosine-N 1  -oxides in the prevention and treatment of vaccinia virus infections are disclosed.

This invention was made with government support awarded by the U.S. Army Medical Research Institute of Infectious Diseases under Contract No. DAMD17-86-C-6011. The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

This invention relates to certain novel substituted 1-(benzyloxy)adenosines and to the use of substituted 1-(benzyloxy)adenosines and adenosine-N¹ -oxides in the prevention and treatment of vaccinia virus infections.

Vaccinia virus has been used historically to prevent smallpox infections. Although the use of vaccinia virus for this purpose is usually considered to be safe, significant complications to the vaccine can occur. These complications include disseminated vaccinia (1 in 25,000 vaccinees) and vaccinia gangrenosum (1 in approximately 20,000 individuals). These complications are rarely life threatening; however, they are of a morbid nature being debilitating and resulting in a loss of work time.

Currently, genetically engineered strains of vaccinia virus are under evaluation as vectors for delivering antigens to prevent other viral infections. The increased use of vaccinia virus strains due to their usefulness as vectors could be expected to increase the incidence of vaccinia virus infections. Therefore, it would be desirable to have an antiviral drug useful for the prevention and treatment of complications associated with the administration of vaccinia.

Shannon et al, J. Med. Chem. 17, 361-363 discloses the compounds adenosine 1-oxide, 1-methyladenosine, 2-methyladenosine, N-hydroxyadenosine, 2'-deoxyadenosine 1-oxide, 1-benzyloxyadenosine, 1-(2-methylbenzyloxy)adenosine fluoroborate, 1-(3-methylbenzyloxy)adenosine hydrobromide, 1-(4-methylbenzyloxy)adenosine hydrobromide, 1-(3-fluorobenzyloxy)adenosine fluoroborate, 1-(4- fluorobenzyloxy)adenosine fluoroborate, and 1-(4-nitrobenzyloxy) adenosine fluoroborate, and reports their in vitro antiviral activity against a number of animal viruses, including vaccinia virus (strain Lederle chorioallantoic).

SUMMARY OF THE INVENTION

It has now been found that certain adenosine-N¹ -oxides and substituted 1-(benzyloxy)adenosines are potent inhibitors of vaccinia virus in an animal model, and would be useful in the treatment of vaccinia virus disease such as complications arising from the use of the vaccinia virus as a vaccine or as a vector. According to the method of this invention, there is administered to a host animal, including man, afflicted with a viral infection caused by vaccinia virus or exposed to vaccinia virus by the administration of the virus as a vaccine or vector, and in need of preventative treatment a therapeutically or prophylactically effective amount of a compound selected from the group of the following adenosine N¹ oxides and substituted 1-(benzyloxy) adenosines ##STR1## where R is hydrogen or methyl and R¹ is ribosyl or 2'-deoxyribosyl and ##STR2## where R is hydrogen or methyl, R¹ is ribosyl or 2'-deoxyribosyl and R² is alkyl or substituted arylalkyl.

According to another aspect of this invention, there are provided certain novel substituted 1-(benzyloxy) adenosines having useful antiviral activities and represented by the formula ##STR3## where X is perchlorate, hydrogen or fluoroborate,

R is hydrogen or methyl

R¹ is ribosyl or 2'-deoxyribosyl, and

R² is a member selected from the group consisting of the following substituted arylalkyl groups: ##STR4##

DETAILED DESCRIPTION OF THE INVENTION

Adenosine-N¹ -oxide is synthesized by reacting adenosine with m-chloroperoxybenzoic acid in methanol. 2'-Deoxyadenosine-N¹ -oxide and 6-methylamino-9-β-D-ribofuranosylpurine-N¹ -oxide were prepared in a similar manner.

1-(Substituted benzyloxy) adenosines are prepared by reacting an adenosine-N¹ -oxide with the appropriate benzyl bromide. Perchlorate salts are prepared by the addition of ammonium perchlorate.

The following examples illustrate the preparation of the compounds described above.

All solvents and materials were reagent grade and were either used as received or purified as required. ¹ H NMR and ¹³ C NMR spectra were run with a Nicolet NMC NT-300 NB spectrometer operating at 300.65 MHz with tetramethylsilane as an internal reference. Chemical shifts (δ) for multiplets were measured from the appropriate centers. The mass spectral data were obtained from a Varian MAT 311A mass spectrometer in fast atom bombardment (FAB) or electron-impact (EI) mode (direct probe temperature 20° C.), as indicated. Infrared data were obtained with a Nicolet 10-MX spectrometer. In most cases only strong or medium peaks in the 1800-600 cm⁻¹ range were reported. UV absorption spectra were determined in the appropriate [pH 1 (0.1N HCl), pH 7 buffer, and pH 13 (0.1N NaOH)] solutions with a Cary 17 spectrophotometer or a Perkin Elmer Model Lambda 9 UV/VIA/NIR spectrophotometer. Melting point data was obtained with a Mel-Temp Capillary Melting point apparatus, and all melting points were uncorrected. Elemental analysis data were obtained either from Atlantic Microlab of Atlanta, Ga. or The Southern Research Institute of Birmingham, Ala.

In the following examples, MeOH is methanol, EtOH is ethanol and MCPBA is m-chloroperoxybenzoic acid.

EXAMPLE 1

Adenosine-N¹ -oxide (1a). In a 1-L round-bottomed flask protected with a calcium sulfate drying tube was placed a 5.0 g (18.7 mmol) of adenosine and 500 mL of methanol. The mixture was stirred at room temperature and 4.85 g (22.5 mmol) of m-chloroperoxybenzoic acid (MCPBA) was added in 7-10 portions over 2 hours. If thin-layer chromatography after 15-20 hours of stirring indicates the presence of starting material an additional 0.5 g (2.9 mmol) of MCPBA should be added and the reaction stirred an additional 4 hours. If the TLC continues to show starting material another portion of MCPBA must be added and the stirring continued overnight. After the TLC showed little or no starting material left the reaction mixture was poured slowly in 2 L of ethyl acetate with good stirring. After having been stirred 2 hours, the product was collected, washed with ethyl acetate, and dried in vacuo over phosphorus pentoxide: yield 4.6 g. Melting point and elemental analysis data are set forth in Table I.

UV λ_(max) 212 nm (ε28,300), 257 (12,500), 265 (sh) at pH 1; 232 (41,900), 262 (8,300), 295 (2,400) at pH 7; 231 (24,900), 267 (8,800), 275 (sh), 307 (4,700) at pH 13; 235 (41,400), 263 (7,700), 304 (2,250) in EtOH; MS (FABMS) m/e 284 (M+1); IR 1670, 1500, 1225, 1210, 1135 sh, 1125, 1085, 1060, 640 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.57, 3.69 (2 m, 2, J_(5'a),5'b =12.0, CH₂₋ 5'), 3.96 (apparent q, 1, J₄,5'b =4.0 Hz, J_(4'),5'a =4.1 Hz, H-4'), 4.16 (apparent q, 1, J_(3'), 4' =3.7 Hz, H- 3'), 4.56 (apparent q, 1, J_(2'), 3 '=5.0 Hz, H-2'), 5.09 (apparent t, 1, 5'-OH), 5.28 (apparent d, 1, 3'-OH), 5.64 (apparent d, 1, 2'-OH), 5.89 (d, 1, H-1'), 8.55 (s, 1, H-2), 8.64 (s, 1, H-8).

EXAMPLE 2

2'-Deoxyadenosine-N¹ -oxide (1b) was prepared using the procedure set forth in Example 1. Table 1 sets forth the amount of reactant used. The same ratio of reactants and solvents was maintained. Melting point and elemental analysis data are set forth in Table 1. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 258 nm (12,520) at pH 1; 261 (8,490) at pH 7; 268 (8,600) at pH 13; MS (FAB) m/e 268 (M+1); IR 1680, 1499, 1380, 1233, 1213, 1091, 1075, 1070, 1025 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 2.32 (m, 1, J_(2'a),3' =3.6 Hz, J_(1'),2'a =6.2 Hz, H-2'a), 2.70 (m, 1, J_(2'),3' =5.9 Hz, J_(1'),2' =7.2 Hz, J_(2'a),2' =13.3 Hz, H-2'b), 3.52, 3.60 (2 m, 2, J_(5'a),5'b =11.8 Hz, CH₂ -5'), 3.87 (apparent q, 1, J_(4'),5'a =J_(4'),5 'b=4.7 Hz, H-4'), 4.41 (apparent q, 1, J_(3'),4' =2.7 Hz, J_(2'a),3' =3.6 Hz, J_(2'b),3' =5.9 Hz, H-3'), 4.98 (apparent t, 1, J_(5'),5'-OH =5.0 Hz, 5'-OH), 5.38 (apparent d, 1, J_(3'),3'-OH = 3.8 Hz, 3'-OH), 6.33 (apparent t, 1, J_(1'),2'a =6.2 Hz, J_(1'),2'b =7.2 Hz, H-1'), 8.51 (s, 1, H-2), 8.63 (s, 1, H-8). Anal. Calcd for C₁₀ H₁₃ N₅ O₄.0.40H₂ O: C, 43.76; H, 5.07; N, 25.52. Found: C, 43.83; H, 5.06; N, 25.28.

EXAMPLE 3

6-Methylamino-9-β-D-ribofuranosylpurine-N¹ -oxide (1c).¹⁻³ was prepared using the procedure set forth in Example 1. Table 1 sets forth the amount of reactant used. The same ratio of reactants and solvents was maintained. Melting point and elemental analysis data are set forth in Table 1. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 215 nm (25,800), 262 nm (13,900) at pH 1; 235 (37,900), 270 (9,800) at pH 7; 235 (38,000), 271 (9,500); MS (FAB) m/e 298 (M+1); IR 1656, 1580, 1500, 1425, 1215, 1090 (broad), 1050, 1025 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.45 (apparent d, 3, NCH₃), 3.54, 3.66 (2 m, 2, J_(4'),5'a =4.0 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 3.93 (apparent q, 1, H-4'), 4.16 (apparent q, 1, J_(3'),4' =3.8 Hz, H-3'), 4.51 (apparent q, 1, J_(2'),3' =5.0 Hz, H-2'), 5.07 (t, 1, J.sub. 5',5' -OH=5.5 Hz, OH-5'), 5.24 (d, 1, J_(3'),3'-OH =5.1 Hz, OH-3'), 5.59 (d, 1, J_(2'),2'-OH =5.9 Hz, OH-2'), 5.88 (d, 1, J_(1'),2' =5.5 Hz, H-1'), 8.39 (br d, 1, CH₃ N-H), 8.55 (s, 1, H-2), 8.62 (s, 1, H-8).

EXAMPLE 4

General procedure for the preparation of 1-(Substituted benzyloxy)adenosines, perchloric acid salts.

In a 100-mL round-bottomed flask equipped with a magnetic stirrer and a calcium sulfate drying tube was placed 2.5 g (8.83 mmol) of adenosine-N¹ -oxide (1), 50 mL of molecular sieve (4A) dried N,N-dimethyl acetamide (DMAC), and 26.5 mmol of the appropriate benzyl bromide was added to the well-stirred suspension. The benzyl bromide used depends upon the product desired. For example, to make 1-(3-methylbenzyloxy)adenosine, the benzyl bromide use is 3-methylbenzyl bromide. The mixture was stirred for 2 hours after complete solution was achieved. The reaction mixture was poured into 300-500 mL of anhydrous ether with slight swirling. After the product stuck to the walls of the flask the supernatant was decanted. The gummy residue was washed with 400 mL of ether, decanted, again covered with 400 mL of ether, and ground to a powder. The powder was allowed to settle, the ether was decanted and the residue was dried in a stream of argon. The residue was dissolved in 25 mL of H₂ O and added with stirring to a warm solution of 5 g (42.6 mmol) of ammonium perchlorate dissolved in 25 mL of H₂ O. The product crystallized upon scratching and chilling. One recrystallization from H₂ O and drying at either 56° C. or 78° C. for 16 hours over phosphorus pentoxide usually yielded an analytical sample (see Table 2).

EXAMPLE 5

1-(3-Methylbenzyloxy)adenosine, perchloric acid salt (2a) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV δ_(max) 258 nm (12,400) at pH 1; 258 (12,400) at pH 7; 257 (12,550) at pH 13; MS (FAB) m/e 388 (M+1); IR 1690, 1224, 1088 broad, 623 cm⁻¹, ¹ H NMR (Me₂ SO-d₆) δ 2.35 (s, 3, CH₃), 3.58, 3.69 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =4.0 Hz, J_(5'b),5'a =12.0 Hz, CH₂ -5'), 4.01 (apparent q, 1, H-4'), 4.15 (apparent t, 1, J_(3'),4' 3.8 Hz, H-3'), 4.48 (apparent t, 1, J_(2'),3' =4.9 Hz, H-2'), 5.00-5.16 (br s, 1, 5'-OH), 5.22-5.43 (m, 1, 3'-OH), 5.36 (s, 2, O-CH Ar), 5.50-5.62 (br s, 1, 2'-OH), 5.93 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.25-7.50 (m, 4, H-Ar), 8.81 (s, 1, H-8), 8.95 (s, 1, H-2), 9.72 (br s, 1, H-N.sup.⊕ H₂), 10.40 (br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 6

1-(4-Methylbenzyloxy)adenosine, perchloric acid salt (2b) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (12,900) at pH 1; 259 (12,600) at pH 7; 258 (12,510) at pH 13; MS (FAB) m/e 388 (M+1); IR 1679, 1505, 1425, 1220, 1100 (broad), 855, 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 2.34 (s, 3, H-ArCH₃), 3.59, 3.67 (2 m, 2, J_(4'), 5'a =3.8 Hz, J_(4'),5'b =4.0 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.9 Hz, H-3'), 4.49 (apparent t, 1, J_(2'),3' =4.8 Hz, H-2'), 5.09, 5.32, 5.59 (3 br s, 3, 5', 3', 2'-OH), 5.37 (s, 2, OCH₂ Ar), 5.94 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.26 (d, 2, Ar-H-3,5), 7.54 (d, 2, Ar-H-2,6), 8.81 (s, 1, H-8), 8.92 (s, 1, H-2), 9.73, 10.39 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 7

1-(2-Methylbenzyloxy)adenosine, perchloric acid salt (2c) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,420) at pH 1; 259 (13,260) at pH 7; 258 (13,210) at pH 13; MS (FAB) m/e 388 (M +1); IR 1687, 1510, 1415, 1227, 1127, 1083 (broad), 916, 880, 767, 690, 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 2.47 (s, 3, CH₃), 3.57, 3.68 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b 32 4.0 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.15 (apparent t, 1, J_(3'),4' =3.8 Hz, H-3'), 4.47 (br s, 1, J_(2'),3' =4.9 Hz, H-2'), 5.08 (br s, 1, 5'-OH), 5.32 (br s, 1, 3'-OH), 5.46 (s, 2, OCH₂ Ar), 5.60 (br s, 1, 2'-OH), 5.92 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.35 (m, 4, H-Ar), 8.61 (s, 1, H-2), 8.83 (s, 1, H-8), 9.79 (br s, 1, H-N.sup.⊕ H₂), 10.48 (br s, 1, H-N.sup.⊕ CH₂); ¹³ C NMR (Me₂ SO-d₆) δ 18.64 (CH₃), 60.83 (C-5'), 69.92 (C-3'), 74.46 (C-2'), 79.56 (C-OCH₂ Ar), 85.83 (C-4'), 87.74 (C-1'), 119.84 (C-5), 125.84 (Ar-C3), 129.93 (Ar-C6), 130.45 (Ar-C4), 131.34 (Ar-C2), 138.13 (Ar-C1), 142.84 (C-8), 144.40 (C-2), 145.17 (C-4), 148.32 (C-6).

EXAMPLE 8

1-(4-Methoxybenzyloxy)adenosine, perchloric acid salt (2d) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 258 nm (13,900) at pH 1; 259 (12,100) at pH 7; 259 (11,400) at pH 13; MS (FAB) m/e 404 (M+1); IR 1684, 1610, 1516, 1252, 1229, 1180, 1100 broad, 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.58, 3.70 (2 m, 2, CH₂ -5'), 3.79 (s, 3, OCH₃), 3.99 (apparent q, 1, H-4'), 4.16 (apparent q, 1, H-3'), 4.49 (apparent q, 1, H-2'), 5.09 (apparent t, 1 OH-5'), 5.33 (apparent d, 1 OH-3'), 5.35 (s, 2, OCH₂ Ar), 5.60 (d, 1, 2, Ar-H-2,6), 8.80 (s, 1, H-8), 8.87 ( s, 1, H-2), 10.02 (br OH-2'), 5.93 (d, 1, H-1'), 6.99 (d, 2, Ar-H-3,5), 7.69 (d, 2, Ar-H-2,6), 8.80 (s, 1, H-8), 8.87 (s, 1, H-2), 10.02 (br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 9

1-(3-Methoxybenzyloxy)adenosine, perchloric acid salt (2e) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 260 nm (13,200) at pH 1; 260 (12,700) at pH 7; 258 (13,100) at ph 13; MS (FAB) m/e 404 (M+1); IR 1683, 1605, 1510, 1495 1435 1270 1100 (broad), 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.56, 3.68 (2 m, 2, CH₂ -5'), 3.78 (s, 3, OCH₃), 3.98 (apparent q, 1, H-4'), 4.14 (apparent q, 1, H-3'), 4.47 (apparent q, 1, H-2'), 5.07 (apparent t, 1 OH-5'), 5.31 (apparent d, 1 OH-3'), 5.36 (s, 2, OCH₂ Ar), 5.59 (apparent d, 1, OH-2'), 5.92 (d, 1, H-1'), 7.03 (m, 1, Ar-H-4), 7.19 (d, 1, Ar-H-6), 7.28 (apparent t, 1, Ar-H-2), 7.37 (t, 1, Ar-H-5), 8.76 (s, 1, H-8), 8.88 (s, 1, H-2), 9.95 (br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 10

1-(1-Phenylethyloxy)adenosine, perchloric acid salt (2f) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (12,400) at pH 1; 259 (12,500) at pH 7; 258 (12,900) at pH 13; MS (FAB) m/e 388 (M+1); IR 1691, 1510, 1430, 1400, 1325, 1225, 1100 (broad), 875, 720, 705, 635, 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 1.80 (d, 3, CH₃), 3.55, 3.65 (2 m, 2, CH₂ -5'), 3.95 (apparent q, 1, H-4'), 4.12 (apparent t, 1, H-2'), 4.43 (apparent t, 1, H-2'), 5.07, 5.31, 5.68 (3 apparent s, 3, OH-5', 3'-2'), 5.71 (apparent q, 1, OCHAr), 5.90 (m, 1, H-1'), 7.42, 7.59 (2 m 5, Ar-H), 8.77 (apparent t, 2, H-8,2), 9.53, 10.32 (2 br s, 2, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 18.61 (C-CH₃), 60.80 (C-5'), 69.88 (C-3'), 74.39 (C-2'), 85.83 (C-4'), 87.65 (C-1'), 88.60 (C-OCHAr), 118.97 (C-5), 128.49, 128.54 (Ar-C-2,3,5,6), 129.85 (Ar-C-4), 136.05 (Ar-C-1), 142.83 (C-8), 144.72 (C-2), 144.89 (C-4), 148.61 (C-6).

EXAMPLE 11

1-(2-Fluorobenzyloxy)adenosine, perchloric acid salt (2g) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,400) at pH 1; 259 (13,100) at pH 7; 257 (12,500) at pH 13; MS (FAB) m/e 392 (M+1); IR 1686, 1515, 1415, 1227, 1100 (broad), 770, 622 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.58, 3.69 (2 m, 2, CH₂ -5'), 3.99 (apparent q, H-4'), 4.15 (apparent t, 1, H-3'), 4.48 (apparent s, 1, H-2'), 5.09, 5.33 (2 br s, 2, OH-5'3'), 5.52 (s, 2, OCH₂ Ar), 5.60 (br s, 1, OH-2'), 5.94 (d, 1, H-1'), 7.30, 7.56, 7.69 (3 m, 4, Ar-H), 8.79 (s, 1, H-2), 8.82 (s, 1, H-8), 9.78, 10.44 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 12

1-(3-Fluorobenzyloxy)adenosine, perchloric acid salt (2h) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,700) at pH 1; 259 (13,700) at pH 7; 258 (13,100) at pH 13; MS (FAB) m/e 392 (M+1); IR 1684, 1507, 1100 (broad), 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.69 (2 m, 2, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, H-3'), 4.49 (apparent t, 1, H-2'), 5.43 (s, 2, OCH₂ Ar), 5.97 (d, 1, H-1'), 7.34, 7.52, 7.63 (3 m, 4, Ar-H), 8.83 (s, 1, H-8), 9.05 (s, 1, H-2), 9.78, 10.44 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 13

1-(4-Fluorobenzyloxy)adenosine, perchloric acid salt (2i) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 258 nm (12,500) at pH 1; 258 (12,300) at pH 7; 257 (12,400) at pH 13; MS (FAB) m/e 392 (M+1); IR 1690, 1511, 1226, 1100 broad, 874, 855, 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.70 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =4.0 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.17 (apparent t, 1, J_(3'),4' =3.8 Hz, H-3'), 4.50 (apparent t, 1, J_(2'3') =4.9 Hz, H-2'), 5.09 (br s, 1, 5'-OH), 5.32 (br s, 1, 3'-OH), 5.41 (s, 2, O-CH₂ Ar), 5.59 (br d, 1, 2'-OH), 5.95 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.31 (t, 2, J_(H),F =8.8 Hz, H-3",5"), 7.75 (m, 2, J_(H),F =5.6 Hz, H-2",6"), 8.82 (s, 1, H-8), 9.00 (s, 1, H-2), 9.75 (br s, 1, H-N.sup.⊕ H₂), 10.39 (br s, 1, H-N.sup.⊕ H₂).

EXAMPLE 14

1-(2,4-Difluorobenzyloxy)adenosine, perchloric acid salt (2j) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,500) at pH 1; 259 (13,300) at pH 7; 257 (13,000) at pH 13; MS (FAB) m/e 410 (M +1); IR 1690, 1620, 1508, 1100 (broad), and 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆)δ 3.58, 3.70 (2 m, 2, J_(4'),'a =3.7 Hz, J_(4'),5'b =4.0 Hz, J_(5'a),5'b =12.1 Hz, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.16 (apparent s, 1, J_(3'),4' =3.9 Hz, H-3'), 4.48 (apparent q, 1, J_(2'),3' =4.9 Hz, H-2'), 5.09, 5.33 (2 apparent s, 2, OH-5',3'), 5.47 (s, 2, OCH₂ Ar), 5.60 (apparent d, 1, OH-2'), 5.94 (d, 1, J_(1'),2' =5.3 Hz, H-1'), 7.22, 7.39 (2 m 2, Ar-H-3,5), 7.76 (q, 1, Ar-H-6), 8.81 (s, 2, H-8,2), 9.79, 10.44 (2 br s, 2, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.86 (C-5'), 69.95 (C-3'), 74.36 (C-OCH₂ Ar), 74.48 (C-2'), 85.89 (C-4'), 87.73 (C-1'), 104.24 (Ar-C-3), 111.85 (Ar-C-5), 117.00 (Ar-C-1), 119.39 (C-5), 134.60 (Ar-C-6), 142.87 (C-8), 144.55 (C-2), 145.25 (C-4), 148.41 (C-6), 161.55, 163.47 (Ar-C-2,4).

EXAMPLE 15

1-(3,4-Difluorobenzyloxy)adenosine, perchloric acid salt (2k) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,000) at PH 1; 259 (13,400) at pH 7; 258 (12,900) at pH 13; MS (FAB) m/e 410 (M+1); IR 1687, 1522, 1440, 1294, 1100 (broad), and 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.69 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =3.7 Hz, J_(5'a),5'b =12.1 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.17 (apparent t, 1, J_(3'),4' =3.9 Hz, H-3'), 4.50 (br s, 1, J_(2'),3' =4.9 Hz, H-2'), 5.10, 5.35, 5.60 (3 br s, 49 3, OH-5',3',2'), 5.38 (s, 2, OCH₂ Ar), 5.95 ( d, 1, J_(1'),2' = 5.3 Hz, H-1'), 7.55, 7.88 (2 m 3, Ar-H-2,5,6), 8.82 (s, 1, H-8), 9.03 (s, 1, H-2), 9.76, 10.44 (2 br s, 2, H-N.sup.⊕ CH₂).

EXAMPLE 16

1-(2-Trifluoromethylbenzyloxy)adenosine, perchloric acid salt (21) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 258 nm (13,100) at pH 1; 258 (12,900) at pH 7; 257 (12,700) at pH 13; MS (FAB) m/e 442 (M+1); IR 1682, 1317, 1177, 1108 (broad), 778, 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ3.58, 3.68 (2 m, 2, J_(4'),5'a =J_(4'),5'b =3.9 Hz, J_(5'a),5'b =32 12.1 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.17 (apparent t, 1, J_(3'),4' =3.9 Hz, H-3'), 4.49 (apparent t, 1, J_(2'),3' =4.9 Hz, H-2'), 5.09 (br s, 1, 5'-OH), 5.32 (br s, 1, 3'-OH), 5.60 (br s, 1, 2'-OH), 5.61 (s, 2, O-CH.sub. 2 Ar), 5.94 (d, 1, J_(1'),2' =5.3 Hz, H-1'), 7.80 (m 4, H-Ar), 8.68 (s, 1, H-2), 8.83 (s, 1, H-8), 9.81, 10.47 (2 br s, 2, H-NCH₂).

EXAMPLE 17

1-[3,5-Bis(trifluoromethyl)benzyloxy]adenosine, perchloric acid salt (2m) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (12,600) at pH 1; 259 (12,280) at pH 7; 257 (12,100) at pH 13; MS (FAB) m/e 510 (M+1); IR 1684, 1366, 1282, 1129 (broad), 684, and 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆)δ3.61, 3.68 (2 m, 2, J_(4'), 5'a =3.8 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =11.9 Hz, CH₂ -5'), 4.01 (apparent q, 1, H-4'), 4.18 (apparent t, 1, J_(3'),4' =3.8 Hz, H-3'), 4.52 (apparent t, 1, J_(2'),3' =4.9 Hz, H-2'), 5.08 (br s, 1, 5'-OH), 5.34 (br s, 1, 3'-OH), 5.59 (br s, 1, 2'-OH), 5.56 (s, 2, OCH₂ Ar), 5.98 (apparent d, 1, J_(1'),2' =5.41 Hz, H-1'), 8.26 (s, 1, Ar-H-4), 8.52 (s, 1, Ar-H-6), 8.84 (s, 1, H-8), 9.30 (s, 1, H-2), 9.84, 10.51 (2 br s, 2, H-N.sup.⊕ CH₂). ¹³ C NMR (Me₂ SO-d₆) δ 61.02 (C-5'), 70.15 (C-3'), 74.62 (C-2'), 79.74 (C-OCH₂ Ar), 86.08 (C-4'), 87.96 (C-1'), 119.55 (C-5), 123.21 (Ar-C-4), 123.23 (2 C-CF₃), 130.35 (Ar-C-3,5), 131.74 (Ar-C-2,6), 135.37 (Ar-C-1), 143.04 (C-8), 145.14 (C-2), 145.41 (C-4), 148.39 (C-6).

EXAMPLE 18

1-[2,4-Bis(trifluoromethyl)benzyloxy]adenosine, perchloric acid salt (2n) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,240) at pH 1; 259 (12,710) at pH 7; 257 (12,090) at pH 13; MS (FAB) m/e 510 (M+1); IR 1684, 1348, 1304, 1281, 1123 (broad), 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.60, 3.69 (2 m, 2, J_(4'),5'a =3.8 Hz, J_(4'),5'b =3.6 Hz, J_(5'a),5'b =12.3 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.9 Hz, H-3'), 4.50 (apparent t, 1, J_(2'),3' =5.0 Hz, H-2'), 5.09 (br s, 1, 5'-OH), 5.33 (br s, 1, 3'-OH), 5.60 (br s, 1, 2'-OH), 5.71 (s, 2, OCH₂ Ar), 5.93 (apparent d, 1, H-1'), 8.15 (m, 2, Ar-H-3,6), 8.27 (apparent d, 1, Ar-H-5), 8.84 (s, 1, H-8), 8.91 (s, 1, H-2), 9.84, 10.48 (2 br s, 2, H-N.sup.⊕ CH₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.94 (C-5'), 70.04 (C-3'), 74.58 (C-2'), 76.36 (C-OCH₂ Ar), 85.99 (C-4'), 87.81 (C-1'), 119.77 (C-5), 123.08, 123.14, 123.21 (2 C-CF₃, Ar-C-3), 128.04, 129.71, 130.03, 132.35 (Ar-C-2,4,5,6), 135.91 (Ar-C-1), 142.86 (C-8), 144.53 (C-2), 145.31 (C-4), 148.53 (C-6).

EXAMPLE 19

1-(2-Chlorobenzyloxy)adenosine, perchloric acid salt (2o) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 260 nm (12,690) at pH 1; 259 (12,550) at pH 7; 258 (12,510) at pH 13; MS (FAB) m/e 408 (M+1); IR 1689, 1509, 1220, 1100 (broad), 931, 860, 774, 769, 645, 640, 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆)δ 3.58, 3.68 (2 m, 2, J_(4'), 5'a =3.9 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =4.0 Hz, H-3'), 4.49 (apparent t, 1, J_(2'),3' =4.6 Hz, H-2'), 5.09 (br s, 1, 5'-OH), 5.31 (br s, 1, 3'-OH), 5.54 (s, 2, OCH₂ Ar), 5.60 (br s, 1, 2'-OH), 5.93 (d, 1, J_(1'),2' =5.3 Hz, H-1'), 7.42-7.78 (m, 4, H-Ar), 8.70 (s, 1, H-2), 8.83 (s, 1, H-8), 9.82, 10.48 (2 br s, 2, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.82 (C-5'), 69.91 (C-3'), 73.45 (C-2'), 78.14 (C-OCH₂ Ar), 85.84 (C-4'), 87.71 (C-1'), 119.44 (C-5), 127.42, 129.50, 131.70 (Ar-C-3,4,5), 129.99 (Ar-C-2), 132.94 (Ar-C-6), 134.02 (Ar-C-1), 142.84 (C-8), 144.33 (C-2), 145.19 (C-4), 148.39 (C-6).

EXAMPLE 20

1-(3-Chlorobenzyloxy)adenosine, perchloric acid salt (2p) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR. ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (12,910) at ph 1; 259 (12,560) at pH 7; 258 (12,560) at pH 13; MS (FAB) m/e 408 (M+1); IR 1694, 1620, 1575, 1510, 1430, 1415, 1380, 1220, 1075 (broad), 885, 785, 685, 622 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆)δ3.59, 3.69 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =4.0 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.17 (apparent t, 1, J₃₊,4' =3.9 Hz, H-3'), 4.50 (apparent t, 1, J_(2'),3' =4.7 Hz, H-2'), 5.09 (br s, 1, 5'-OH), 5.33 (br s, 1, 3'-OH), 5.40 (s, 2, OCH₂ Ar), 5.60 (br s, 1, 2'-OH), 5.96 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.48-7.88 (m, 4, H-Ar), 8.82 (s, 1, H-8 ), 9.10 (s, 1, H-2), 9.78, 10.44 (2 br s, 1, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.85 (C-5'), 69.95 (C-3'), 74.46 (C-2'), 80.63 (C-OCH₂ Ar), 85.87 (C-4'), 87.78 (C-1'), 119.34 (C-5), 129.23, 129.54, 130.41 (Ar-C-2,4,6), 130.24 (Ar-C-5), 133.00 (Ar-C-3), 134.32 (Ar-C-1), 142.84 (C-8), 144.82 (C-2,), 145.20 (C-4), 148.26 (C-6).

EXAMPLE 21

1-(2-Nitrobenzyloxy)adenosine, perchloric acid salt (2q) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

US λ_(max) 259 nm (18,170) at pH 1; 259 (18,090) at pH 7; 257 (16,890) at pH 13; MS (FAB) m/e 419 (M+1); IR 1685, 1538, 1530, 1510, 1347, 1105 (broad), 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.68 (2 m, 2, J_(4'),5'a =3.7 Hz J_(4'),5'b =4.0 Hz, H_(5'a),5'b =12.1 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.9 Hz, H-3'), 4.49 (apparent t, 1, J_(2'),3' =4.9 Hz, H-2'), 5.08 (br s, 1, 5'-OH), 5.32 (br s, 1, 3'-OH), 5.60 (br s, 1, 2'-OH), 5.76 (s, 2, OCH₂ Ar), 5.95 (d, 1, J_(1'),2' =5.35 Hz, H-1'), 7.75 (m, 1, Ar-H-4), 7.90 (m, 1, Ar-H-5), 7.99 (apparent d, 1, Ar-H-3), 8.22 (apparent d, 1, Ar-H-6), 8.83 (s, 1, H-8), 8.94 (s, 1, H-2), 9.80, 10.46 (br s, 2, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.83 (C-5'), 69.92 (C-3'), 74.46 (C-2'), 77.01 (C-OCH₂ Ar), 85.84 (C-4'), 87.77 (C-1'), 119.54 (C-5), 124.81 (Ar-C-3), 128.32 (Ar-C-1), 130.29 (Ar-C-4), 131.11 (Ar-C-5), 134.03 (Ar-C-6), 142.79 (C-8), 144.45 (C-2), 145.21 (C-4), 147.54 (Ar-C-2), 148.36 (C-6).

EXAMPLE 22

1-(3-Nitrobenzyloxy)adenosine, perchloric acid salt (2r) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR. ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (19,400) at pH 1; 259 (19,100) at pH 7; 258 (17,560) at pH 13; MS (FAB) m/e 419 (M+1); IR 1691, 1620, 1533, 1511, 1352, 1225, 1090 (broad), 900, 740, 622 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.60, 3.71 (2 m, 2, J_(4'),5'a =J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.01 (apparent q, 1, H-4'), 4.18 (apparent t, 1, J_(3'),4' =3.7 Hz, H-3'), 4.51 (apparent t, 1, J_(2'),3' =4.8 Hz, H-2'), 5.10 (br s, 1, 5'-OH), 5.34 (br s, 1, 3'-OH), 5.55 (s, 2, OCH₂ Ar), 5.60 (br s, 1, 2'-OH), 5.97 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.80 (t, 1, H-Ar5), 8.17 (d, 1, H-Ar6), 8.35 (m, 1, H-Ar4), 8.67 (s, 1, H-Ar2), 8.83 (s, 1, H-8), 9.17 (s, 1, H-2), 10.15 (br s, 2, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.88 (C-5') 69.99 (C-3'), 74.49 (C-2'), 80.11 (C-OCH₂ Ar), 85.92 (C-4'), 87.79 (C-1'), 119.42 (C-5), 124.40 (Ar-C5), 125.45 (Ar-C4), 129.95 (Ar-C2), 134.13 (Ar-C6), 137.25 (Ar-C1), 142.87 (C-8), 144.95 (C-2 ), 145.24 (C-4), 147.64 (Ar-C3), 148.31 (C-6).

EXAMPLE 23

1-(4-Nitrobenzyloxy)adenosine, perchloric acid salt (2s) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR. ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 260 nm (22,270) at pH 1; 260 (21,970) at pH 7; 265 (18,550) at pH 13 (slowly decreased); MS (FAB) m/e 419 (M+1); IR 1686, 1524, 1348, 1220, 1090 (broad), 854, 750, 622 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.57, 3.70 (2 m, 2, J_(4'),5'a =4.0 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent q, 1, J_(3'),4' =3.7 Hz, H-3'), 4.50 (apparent q, 1, J_(2'),3' =4.9 Hz, H-2'), 5.09 (t, 1, J_(5'),5'-OH =5.3 Hz, 5'-OH), 5.34 (d, 1, J_(3'),3'-OH = 5.2 Hz, 3'-OH), 5.55 (s, 2, OCH₂ Ar), 5.60 (d, 1, J_(2'),2'-OH =6.1 Hz, 2'-OH), 5.95 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.97 (d, 2, Ar-H-2,6), 8.34 (d, 2, Ar-H-3,5), 8.83 (s, 1, H-8), 9.11 (s, 1, H-2), 10.15 (broad 2, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ60.87 (C-5'), 69.97 (C-3'), 74.53 (C-2'), 80.03 (C-OCH₂ Ar), 85.89 (C-4'), 87.84 (C-1'), 119.43 (C-5), 123.38 (Ar-C-3,5), 131.38 (Ar-C-2,6), 139.45 (Ar-C1), 142.88 (C-8), 144.76 (C-2), 145.24 (C-4 ), 148.01 (Ar-C4), 148.33 (C-6).

EXAMPLE 24

1-(2-Methoxy-5-nitrobenzyloxy)adenosine, perchloric acid salt (2t) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (14,550) and 310 (10,620) at pH 1; 259 (14,510) and 310 (10,870) at pH 7; 311 (11,800) at pH 13; MS (FAB) m/e 449 (M+1); IR 1681, 1595, 1510, 1500, 1490, 1332, 1261, 1212, 1127, 1090 (broad), 1036, 900, 640, and 620 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.68 (2 m, 2, J_(4'),5'a =3.5 Hz, J_(4'),5'b =3.5 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 3.86 (s, 3, CH₃ OAr), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =4.0 Hz, H-3'), 4.49 (apparent t, 1, J_(2'),3' =4.1 Hz, H-2' ), 5.09 (apparent t, 1, J_(5'),5'-OH =4.9 Hz, 5'-OH), 5.33 (apparent d, 1, J_(3'),3'-OH =5.0 Hz, 3'-OH), 5.50 (s, 2, OCH₂ Ar), 5.59 (apparent d, 1, J_(2'),2'-OH =6.0 Hz, 2'-OH, 5.95 (d, 1, J_(1'),2' =5.34 Hz, H-1'), 7.31 (d, 1, Ar-H-3), 8.40 (apparent q, 1, Ar-H-4), 8.56 (d, 1, Ar-H-6), 8.84 (s, 2, H-2,8), 9.74, 10.35 (2 br s, 2, H-NH₂). ¹³ C NMR (Me₂ SO-d₆) δ 56.78 (C-ArOCH₃), 60.86 (C-5'), 69.96 (C-3'), 74.59 (C-2'), 75.61 (C-OCH₂ Ar), 85.89 (C-4'), 87.89 (C-1'), 111.80 (Ar-C-3), 119.35 (C-5), 121.12, (Ar-C-1), 127.77, 128.24 (Ar-C-6,4), 140.31 (Ar-C-5), 142.93 (C-8), 144.52 (C-2), 145.25 (C-4), 148.39 (C-6), 163.21 (Ar-C-2).

EXAMPLE 25

1-(3-Methoxycarbonylbenzyloxy)adenosine, perchloric acid salt (2u) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (12,670) at pH 1; 259 (12,670) at pH 7; 257 (13,410) at pH 13; MS (FAB) m/e 432 (M+1); IR 1710, 1684, 1435, 1315, 1294, 1214, 1100 (broad), 895, 765, and 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.69 (2 m, 2, J_(4'),5'a =3.7 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.1 Hz, CH₂ -5'), 3.89 (s, 3, ArCO₂ CH₃), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.7 Hz, H-3'), 4.50 (apparent t, 1, J_(2'),3' =4.8 Hz, H-2'), 5.10, 5.34, 5.61 (3 br s, 3, 5',3',2'-OH), 5.49 (s, 2, OCH₂ Ar), 5.96 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.64 (t, 1, Ar-H-5), 7.99, 8.06 (d, 2, Ar-H-6,4), 8.33 (s, 1, Ar-H-2), 8.83 (s, 1, H-8), 9.03 (s, 1, H-2), 9.82, 10.44 (2 br s, 2, H-N⁻ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 52.21 (C-ArCO₂ CH₃), 60.88 (C-5'), 69.99 (C-3'), 74.56 (C-2'), 81.02 (C-OCH₂ Ar), 85.90 (C-4'), 87.87 (C-1'), 119.38 (C-5), 128.94 (Ar-C-5), 129.81 (Ar-C-3), 130.32, 131.40, 135.49 (Ar-C-6,4,2), 132.78 (Ar-C-1), 142.87 (C-8), 144.88 (C-2), 145.23 (C-4), 148.33 (C-6), 165.80 (C-ArCO₂ CH₃).

EXAMPLE 26

1-(4-Cyanobenzyloxy)adenosine, perchloric acid salt (2v) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,800) at pH 1; 259 (13,620) at pH 7; 258 (sh) at pH 13; MS (FAB) m/e 399 (M+1); IR 2240, 1687, 1510, 1420, 1385, 1225, 1215, 1075 (broad), 825, 621 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.61, 3.73 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =5.6 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.02 (apparent q, 1, H-4'), 4.19 (apparent q, 1, J_(3'),4' =3.7 Hz, H-3'), 4.51 (apparent q, 1, J_(2'),3' =4.8 Hz, H-2'), 5.11 (t, 1, J_(5'),5'-OH =5.3 Hz, 5'-OH), 5.35 (apparent d, 1, J_(3'),3'-OH = 5.2 Hz, 3'-OH), 5.51 (s, 2, OCH₂ Ar), 5.62 (apparent d, 1, J_(2'),2'-OH =6.1 Hz, 2'-OH), 5.97 (apparent d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.90 (d, 2, Ar-H-3,5), 7.99 (d, 2, Ar-H-2,6), 8.83 (s, 1, H-8), 9.10 (s, 1, H-2), 10.15 (broad, 2,-H-N⁶¹ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.84 (C-5'), 69.94 (C-3'), 74.51 (C-2'), 80.44 (C-OCH₂ Ar), 85.85 (C-4'), 87.83 (C-1'), 112.16 (Ar-C4), 118.38 (C-C≡N), 119.39 (C-5), 131.03 (Ar-C-2,6), 132.26 (Ar-C-3,5), 137.43 (Ar-C1), 142.85 (C-8), 144.71 (C-2), 145.21 (C-4), 148.29 (C-6).

EXAMPLE 27

1-(2-Cyanobenzyloxy)adenosine, perchloric acid salt (2w) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 260 nm (12,700) at pH 1; 259 (12,560) at pH 7; 257 (12,160) at pH 13; MS (FAB) m/e 399 (M+1); IR 2250, 1684, 1505, 1222, 1100 (broad), 772, and 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.68 (2 m, 2, J_(4'),5'a =3.8 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.5 Hz, H-3'), 4.49 (apparent t, 1, J_(2'),3' =4.8 Hz, H-2'), 5.09 (br s, 1, 5'-OH), 5.33 (br s, 1, 3'-OH), 5.60 (br, 1, 2'-OH), 5.60 (s, 2, OCH₂ Ar), 5.94 (apparent d, 1, J_(1'),2' =5.3 Hz, H-1'), 7.70 (t, 1, Ar-H, 4), 7.87, 7.90 (2 m, 2, Ar-H, 3,5), 7.99 (d, 1, Ar-H, 6), 8.81 (s, 1, H-2), 8.83 (s, 1, H-8), 9,92, 10.48 (2 br s, 2, H-N.sup.⊕ H₂).¹³ C NMR (Me₂ SO-d₆) δ 60.81 (C-5'), 69.89 (C-3'), 74.44 (C-2'),78.56 (C-OCH₂ -Ar), 85.83 (C-4'), 87.74 (C-1'), 112.53 (Ar-C-2), 117.12 (C-C≡N), 119.58 (C-5), 130.50, 131.71, 133.20, 133.38 (Ar-C-3,4,5,6), 135.16 (Ar-C-1), 142.81 (C-8), 144.23 (C-2), 145.16 (C-4), 148.38 (C-6).

EXAMPLE 28

1-(3-Cyanobenzyloxy)adenosine, perchloric acid salt (2x) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,500) at pH 1; 259 (12,900) at pH 7; 57 (12,980) at pH 13; MS (FAB) m/e 399 (M+1); IR 2230, 1694, 1510, 1235, 1215, 1090 (broad), 892, 690, 655, 640 and 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.69 (2 m, 2, J_(4'),5'a =3.8 Hz, J_(4'),5'b =3.8 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.7 Hz, H-3'), 4.50 (apparent t, 1, J_(2'),3' =4.7 Hz, H-2'), 5.12 (br s, 1, 5'-OH), 5.34 (br s, 1, 3'-OH), 5.45 (s, 2, OCH₂ Ar), 5.60 (br s, 1, 2'-OH), 5.96 (apparent d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.69 (t, 1, Ar-H-5), 7.96, 8.02 (2 m, 2, Ar-H-4,6), 8.25 (s, 1, Ar-H-2), 8.83 (s, 1, H-8), 9.13 (s, 1, H-2), 9.78, 10.45 (2 br s, 2, H-N.sup.⊕ H₂). ¹³ C NMR (Me₂ SO-d₆) δ 60.87 (C-5'), 69.97 (C-3'), 74.50 (C-2') 80.26 (C-OCH₂ Ar), 85.90 (C-4'), 87.82 (C-1'), 111.44 (Ar-C-3), 118.31 (C-C≡N), 19.41 (C-5), 129.64 (Ar-C-5), 133.18 (Ar-C-4), 133.60 (Ar-C-1), 134.32 (Ar-C-2), 135.33 (Ar-C-6), 142.87 (C-8), 44.84 (C-2), 145.25 (C-4), 148.28 (C-6).

EXAMPLE 29

1-(2-methoxybenzyloxy)adenosine, perchloric acid salt (2y) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

The crude product (4.2 g) was dissolved in about 350 mL hot EtOH, treated with silica gel and filtered through a layer of silica gel. The clear solution was slowly diluted with OH until cloudy, chilled overnight, and the precipitate was collected. This product still contained NH₄ + according to the ¹ H NMR spectrum. However, a second crop obtained from the filtrate which was washed with ether and dried at 56° C. over phosphorus pentoxide overnight was found to be free of NH₄ +. UV λ_(max) 259 nm (12,800) at pH 1; 259 (12,600) at pH 7; 259 (13,000) at pH 13; MS (FAB) m/e 404 (M+1); IR 1684, 1605, 1505, 1500, 1250, 1225, 1100 (broad), 1025, 1015, 860, 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.65 (s, 3, OCH₃), 3.57, 3.68 (2 m, 2, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.15 (apparent q, 1, H-3'), 4.47 (apparent q, 1, H-2'), 5.18 (apparent t, 1, OH-5'), 5.31 (apparent d, 1, OH-3'), 5.42 (s, 2, OCH₂ Ar), 5.59 (apparent d, 1, OH-2'), 5.93 (d, 1, H-1'), 7.02 (m, 1, Ar-H-4,5), 7.48 (m, 2, Ar-H-3,6), 8.65 (s, 1, H-2), 8.80 (s, 1, H-8), 9.54, 10.44 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 30

1-(3,4-Dimethylbenzyloxy)adenosine, perchloric acid salt (2z) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,300) at pH 1; 259 (13,300) at pH 7; 258 (13,600) at pH 13; MS (FAB) m/e 402 (M+1); IR 1691, 1510, 1100 (broad), 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 2.25 (s, 6, Ar-CH₃), 3.58, 3.69 (2 m, 2, J_(4'),5'a =J_(4'),5'b =3.87 Hz, J_(5'a),5'b =12.1 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.85 Hz, H-3'), 4.49 (apparent q, 1, J_(2'),3' =4.88 Hz, H-2'), 5.09 (br s, 1, OH-5'), 5.33 (s, 2, OCH₂ Ar), 5.60 (br d, 1, J_(2'),2'-OH =4.57 Hz, OH-2'), 5.94 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 8.81 (s, 1, H-8), 8.91 (s, 1, H-2), 9.72, 10.41 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 31

1-(3,5-Dimethylbenzyloxy)adenosine, perchloric acid salt (2aa) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (12,900) at pH 1; 259 (13,100) at pH 7; 258 (13,000) at pH 13; MS (FAB) m/e 402 (M+1); IR 1693, 1510, 1225, 1100 (broad), 890, 853, 638, 623 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 2.30 (s, 6, Ar-CH₃), 3.59, 3.69 (2 m, 2, J_(4'),5'a =3.8 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.00 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.8 Hz, H-3'), 4.49 (br s, 1, J_(2'),3' =4.9 Hz, H-2'), 5.09 (br s, 1, OH-5'), 5.32 (s, 2, OCH₂ Ar), 5.60 (br d, 1, OH-2'), 5.95 (d, 1, J_(1'),2' =5.38 Hz, H-1'), 7.11, 7.28 (2 s, 3, Ar-H), 8.82 (s, 1, H-8), 8.96 (s, 1, H-2), 9.72, 10.42 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 32

1-(2,5-Dimethylbenzyloxy)adenosine, perchloric acid salt (2bb) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,100) at pH 1; 259 (13,200) at pH 7; 258 (13,200) at pH 13; MS (FAB) m/e 402 (M+1); IR 1688, 1508, 1415, 1225, 1100 (broad), 915, 900, 880, 875, 825, 685, 655, 622 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 2.26, 2.39 (2 s, 6, Ar-CH₃), 3.58, 3.68 (2 m, 2, J₄,5'a =J_(4'),5'b =3.8 Hz, J_(5'a),5'b =12.1 Hz, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.15 (apparent t, 1, J_(3'),4' =3.9 Hz, H-3'), 4.48 (apparent q, 1, J_(2'),3' =4.9 Hz, H-2'), 5.09 (br s, 1, OH-5'), 5.32 (br s, 1, OH-3'), 5.41 (s, 2, OCH₂ Ar), 5.59 (apparent d, 1, OH-2'), 5.93 (d, 1, J_(1'),2' =5.37 Hz, H-1'), 7.18, 7.20, 7.30 (m, 3, H-Ar), 8.65 (s, 1, H-2), 8.82 (s, 1, H-8), 9.75 10.45 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 33

1-(2,4-Dimethylbenzyloxy)adenosine, perchloric acid salt (2cc) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,300) at pH 1; 259 (13,400) at pH 7; 258 (13,200) at pH 13; MS (FAB) m/e 402 (M+1); IR 1689, 1615, 1510, 1430, 1220, 1100 (broad), 895, 645, 623 cm^(-1;) 1 H NMR (Me₂ SO-d₆) δ 2.31, 2.42 (2 s, 6, Ar-CH₃), 3.57, 3.67 (2 m, 2, CH₂ -5'), 3.98 (apparent q, 1, H-4'), 4.15 (apparent t, 1, H-3'), 4.48 (apparent t, 1, H-2'), 5.09 (br s, 1, OH-5'), 5.33 (br s, 1, OH-3'), 5.40 (s, 2, OCH₂ Ar), 5.60 (br s, 1, OH-2'), 5.91 (d, 1, J_(1'),2' =5.35 Hz, H-1'), 7.03, 7.15, 7.31 (m, 3, H-Ar), 8.52 (s, 1, H-2), 8.82 (s, 1, H-8), 9.76 10.45 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 34

1-Benzyloxyadenosine, perchloric acid salt (2dd) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,100) at pH 1; 259 (13,200) at pH 7; 257 (13,100) at pH 13; MS (FAB) m/e 374 (M+1); IR 1686, 1515, 1415, 1230, 1100 (broad), 755, 622 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.58, 3.68 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =3.9 Hz, J_(5'a),5'b =12.1 Hz, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.15 (apparent q, 1, J_(3'),4' =3.9 Hz, H-3'), 4.49 (apparent q, 1, J_(2'),3' =4.9 Hz, H-4'), 5.18 (apparent t, 1, J_(5'),5 '-OH=5.1 Hz, OH-5'), 5.33 (d, 1, J_(3'),3'-OH =5.1 Hz, OH-3'), 5.42 (s, 2, OCH₂ Ar), 5.60 (d, 1, J_(2'),2'-OH =6.1 Hz, OH-2'), 5.94 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.48, 7.66 (2 m, 5, H-Ar), 8.82 (s, 1, H-8), 8.97 (s, 1, H-2).

EXAMPLE 35

1-(2,6-Difluorobenzyloxy)adenosine, perchloric acid salt (2ee) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (14,000) at pH 1; 259 (13,900) at pH 7; 257 (13,400) at pH 13; MS (FAB) m/e 410 (M+1); IR 1685, 1629, 1515, 1476, 1415, 1405, 1245, 1230, 1100 (broad), 920, 910, 800, 675, 622 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.58, 3.68 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =4.0 Hz, J_(5'a),5'b =12.1 Hz, CH₂ -5'), 3.99 (apparent q, 1, H-4'), 4.16 (apparent t, 1, J_(3'),4' =3.9 Hz, H-3'), 4.49 (apparent q, 1, J_(2'),3' =4.9 Hz, H-2'), 5.10 (br s, 1, OH-5'), 5.33 (br s, 1, OH-3'), 5.57 (s, 2, OCH₂ Ar), 5.62 (apparent d, 1, OH-2'), 5.94 (d, 1, H-1'), 7.23 (t, 2, H-Ar-3,5), 7.63 (m, 1, H-Ar-4), 8.83 (s, 1, H-8), 8.87 (s, 1, H-2), 9.83, 10.48 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 36

1-(3,5-Difluorobenzyloxy)adenosine, perchloric acid salt (2ff) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 259 nm (13,600) at pH 1; 259 (13,500) at pH 7; 257 (12,700) at pH 13; MS (FAB) m/e 410 (M+1); IR 1697, 686 (sh), 1630, 1605, 1455, 1380, 1330, 1230, 1100 (broad), 870, 860 (sh), 845, 665, 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.70 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =4.0 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.01 (apparent q, 1, H-4'), 4.17 (apparent d, 1, J_(3'),4' =3.8 Hz, H-3'), 4.50 (apparent q, 1, J_(2'),3' =4.9 Hz, H-2'), 5.10 (br s, 1, OH-5'), 5.34 (apparent d, 1, H-3), 5.40 (s, 2, OCH₂ Ar), 5.61 (apparent d, 1, J_(2'),2'-OH =6.1 Hz, OH-2'), 5.96 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.39 (m, 1, H-Ar-4), 7.50 (m, 2, H-Ar-2,6), 8.83 (s, 1, H-8), 9.07 (s, 1, H-2), 9.78, 10.47 (2 br s, 2, H-N.sup.⊕ H₂).

EXAMPLE 37

1-(2,5-Difluorobenzyloxy)adenosine, perchloric acid salt (2 gg) was prepared using the procedure set forth in Example 4. The amount of reactant used and the melting point and elemental analysis data are set forth in Table 2. UV, IR, ¹ H NMR, ¹³ C NMR and mass spectrometer data are set forth herein.

UV λ_(max) 260 nm (13,800) at pH 1; 260 (13,800) at pH 7; 258 (13,200) at pH 13; MS (FAB) m/e 410 (M+1); IR 1691, 1510, 1500, 1435, 1240, 1230, 1195, 1100 (broad), 975, 880, 735, 624 cm⁻¹ ; ¹ H NMR (Me₂ SO-d₆) δ 3.59, 3.70 (2 m, 2, J_(4'),5'a =3.9 Hz, J_(4'),5'b =4.0 Hz, J_(5'a),5'b =12.0 Hz, CH₂ -5'), 4.01 (apparent q, 1, H-4'), 4.17 (apparent q, 1, J_(3'),4' =3.8 Hz, H-3'), 4.50 (apparent q, 1, J_(2'),3' =4.9 Hz, H-2'), 5.11 (t, 1, J_(5'),5'-OH =5.3 Hz, OH-5'), 5.35 (d, 1, J_(3'),3'-OH =5.2 Hz, OH-3'), 5.49 (s, 2, OCH₂ Ar), 5.63 (d, 1, J_(2'),2'-OH =6.1 Hz, OH-2'), 5.96 (d, 1, J_(1'),2' =5.4 Hz, H-1'), 7.40, 7.64 (2 m, 3, H-Ar), 8.83 (s, 1, H-8), 8.89 (s, 1, H-2).

In Table 1, Ado is adenosine, dAdo is 2-deoxyadenosine, N⁶ -Me-Ado is 6-methylamino-9-β-D-ribofuranosylpurine, Ado-N¹ -Ox is Adenosine-N¹ -oxide, MeOh is methanol and MCPBA is m-chloroperoxybenzoic acid.

In Table 2, N'-Oxide is adenosine-N¹ -oxide. BrCH₂ R is the appropriate benzyl bromide for the product shown. DMAc is N,N-dimethyl acetamide.

                                      TABLE 1                                      __________________________________________________________________________                                         MF                                         Product   Nucleoside                                                                            MCPBA                                                                               MeOH                                                                               Yield                                                                              Mp cap.                                                                              C, H, N Theory                                                                            Found                           __________________________________________________________________________     Ado-N.sup.1 -Ox                                                                          Ado    5.4 g                                                                               500 mL                                                                             3.7 g                                                                              222-225° C.                                                                   C.sub.10 H.sub.13 N.sub.5 O.sub.5                                                         C = 42.45                       (1a)      5 g             (70%)     C = 42.40, H = 4.63,                                                                      H = 4.64                                  (18.7 mmol)               N = 24.73  N = 24.66                       dAdo-N.sup.1 -Ox                                                                         dAdo   1.2 g                                                                               100 mL                                                                             1.0 g                                                                              219-221° C.                                                                   C.sub.10 H.sub.13 N.sub.5 O.sub.4.                                                        C = 43.83                       (1b)      1.0 g           (100%)                                                                             dec.  0.40H.sub.2 O                                                                             H = 5.06                                  (3.72 mmol)               C = 43.76, H = 5.07,                                                                      N = 25.28                                                           N = 25.52                                  N.sup.6 -Me-Ado-N.sup.1 -Ox                                                              N.sup.6 -Me-Ado                                                                       3.5 g                                                                                80 mL                                                                             620 mg                                                                             142-152° C.                                                                   C.sub.11 H.sub.15 N.sub.5 O.sub.5.                                                        C =  42.12                      (1c)      2.0 g           (30%)     0.25CHCl.sub.3.0.30EtOH                                                                   H = 5.02                                  (7.12 mmol)               C = 42.03, H = 5.08,                                                                      N = 20.74                                                           N = 20.68                                  __________________________________________________________________________

    TABLE 2       Substituted N'-Benzyloxyadenosines      Yield  M.F.  Product N'-Oxide      BrCH.sub.2 R DMAc NH.sub.4 ClO.sub.4 (%) M.P. Cap C, H, N, Theory      Found              2a       ##STR5##       2.7 g(9.54 mmol) 8.82 g(47.7 mmol) 60 mL 5.85 g25 mLH.sub.2 O 2.6(56%)      116-118° C. C.sub.18 H.sub.22 ClN.sub.5 O.sub.9.H.sub.2 OC =      42.74, H = 4.78,N = 13.85 C = 42.70H = 4.67N = 13.70       2b      ##STR6##       2.5 g(8.83 mmol) 4.9 g(26.5 mmol) 50 mL 5 g25 mLH.sub.2 O 1.9 g(44%)      117-122° C.dec. C.sub.18 H.sub.22 ClN.sub.5 O.sub.9.0.25H.sub.2      OC = 43.91, H = 4.61,N = 14.22 C = 44.06H = 4.66N = 14.36       2c      ##STR7##       3.0 g(10.6 mmol) 9.8 g(53 mmol) 60 mL 6.25 g25 mLH.sub.2 O 4.0 g(77%)      122-125° C.dec. C.sub.18 H.sub.22 ClN.sub.5 O.sub.9.0.75H.sub.2      OC = 43.12, H = 4.72,N = 13.97 C = 43.18H = 4.67N = 14.18       2d      ##STR8##       2.5 g(8.83 mmol) 5 mL 50 mL 5 g25 mLH.sub.2       O 2.4 g(55%) 123-129° C. C.sub. 18 H.sub.22 ClN.sub.5       O.sub.10.H.sub.2 OC = 41.43, H = 4.64,N = 13.42 C = 41.33H = 4.68N =      13.32       2e      ##STR9##       2.5 g(8.83 mmol) 5.0 g 50 mL 5 g25 mLH.sub.2       O 2.3 g(52%) 109-119° C. C.sub.18 H.sub.22 ClN.sub.5       O.sub.10.1.25H.sub.2 OC = 41.07, H = 4.50,N = 13.31 C = 40.86H = 4.60N      = 13.32       2f      ##STR10##       2.5 g(8.83 mmol) 5 mL 50 mL 5 g25 mLH.sub.2       O 1.7 g(40%) 128-133° C. C.sub.18 H.sub.22 ClN.sub.5       O.sub.9.H.sub.2 OC = 42.74, H = 4.78,N = 13.84 C = 42.66H = 4.71N =      13.96       2g      ##STR11##       2.5 g(8.83 mmol) 5.0 g 50 mL 5 g25 mLH.sub.2       O 3.3 g(77%) 110-116° C. C.sub.17 H.sub.19 ClFN.sub.5       O.sub.9.H.sub.2 OC = 40.05, H = 4.15,N = 13.74 C = 40.16H = 4.08N =      13.79       2h      ##STR12##       2.5 g8.83 mmol) 5.0 g 50 mL 5 g25 mLH.sub.2       O 3.3 g(77%) 106-114° C. C.sub.17 H.sub.19 ClFN.sub.5       O.sub.9.H.sub.2 OC = 40.05, H = 4.15,N = 13.74 C = 40.20H = 4.03N =      13.81       2i      ##STR13##       3.0 g(10.6 mmol) 10 g(53.0 mmol) 60 mL 6.2 g25 mLH.sub.2 O 2.3 g(44%)      143-146° C. C.sub.17 H.sub.19 ClFN.sub.5 O.sub.9.0.75H.sub.2 OC =      40.40, H = 4.09,N = 13.86 C = 40.20H = 4.13N = 13.99       2j      ##STR14##       2.5 g(8.83 mmol) 5.0 g(24.2 mmol) 50 mL 5 g25 mLH.sub.2 O 1.7 g(38%)      116-120° C. C.sub.17 H.sub.18 ClF.sub.2 N.sub.5 O.sub.9.H.sub.2      OC = 38.68, H = 3.82,N = 13.27 C = 38.58H = 3.66N = 13.40       2k      ##STR15##       2.5 g(8.83 mmol) 5.0 g(24.2 mmol) 50 mL 5 g25 mLH.sub.2 O 1.1 g(24%)      116-122° C. C.sub.17 H.sub.18 ClF.sub.2 N.sub.5       O.sub.9.0.75H.sub.2 OC = 39.02, H = 3.76,N = 13.38 C = 38.98H = 3.60N =      13.48       2l      ##STR16##       3.0 g(10.6 mmol) 10.5 g(43.9 mmol) 85 mL 6.2 g25 mLH.sub.2 O 3.0 g(53%&      108-111° C. C.sub.18 H.sub.19 ClF.sub.3 N.sub.5       O.sub.9.1.5H.sub.2 OC = 38.00, H = 3.90,N = 12.31 C = 37.86H = 3.87N =      12.35       2m      ##STR17##        2.5 g(8.83 mmol) 5.0 g(16.3 mmol) 50 mL 5 g25 mLH.sub.2 O 3.3 g(61%)      113-124° C.dec. C.sub.19 H.sub.18 ClF.sub.6 N.sub.5       O.sub.9.0.75H.sub.2 OC = 36.61, H = 3.15,N = 11.24 C = 36.66H = 3.09N =      11.32       2n      ##STR18##       2.5 g(8.83 mmol) 5.0 g(16.3 mmol) 50 mL 5 g25 mLH.sub.2 O 1.9 g(35%)      114-119° C.dec. C.sub.19 H.sub.18 ClF.sub.6 N.sub.5       O.sub.9.0.25H.sub.2 OC = 37.15, H = 3.04,N = 11.40 C = 37.02H = 3.12N =      11.38       2o      ##STR19##       2.5 g(8.83 mmol) 5.0 g(24.3 mmol) 50 mL 5 g25 mLH.sub.2 O 3.6 g(80%)      126-130° C.dec. C.sub.17 H.sub.19 Cl.sub.2 N.sub.5       O.sub.9.0.25H.sub.2 OC = 39.82, H = 3.83,N = 13.66 C = 39.86H = 3.82N =      13.79       2p      ##STR20##       2.5 g(8.83 mmol) 5.0 g(24.3 mmol) 50 mL 5 g25 mLH.sub.2 O 3.5 g(78%)      140-145° C.dec. C.sub.17 H.sub.19 Cl.sub.2 N.sub.5       O.sub.9.0.50H.sub.2 OC = 39.48, H = 3.90,N = 13.54 C = 39.52H = 3.80N =      13.62       2q      ##STR21##       2.5 g (8.83 mmol) 5.7 g(26.5 mmol) 50 mL 5 g25 mLH.sub.2 O 2.19 g(47%)      117-124° C.dec. C.sub.17 H.sub.19 ClN.sub.6 O.sub.11.H.sub.2 OC =      38.03, H = 3.92,N = 15.66 C = 38.12H = 3.78N = 15.86       2r      ##STR22##       3.0 g(10.6 mmol) 11.4 g(53 mmol) 60 mL 6.25 g25 mLH.sub.2 O 2.1 g(38%)      128-132° C.dec. C.sub.17 H.sub.19 ClN.sub.6 O.sub.11.0.50H.sub.2  C      O = 38.68, H = 3.76,N = 15.92 C = 38.64H = 3.84N = 15.80       2s      ##STR23##       2.5 g(8.83 mmol) 9.5 g(44.2 mmol) 50 mL 5.2 g20 mLH.sub.2 O 3.2 g(70%)      112-122° C.dec. C.sub.17 H.sub.19 ClN.sub.6 O.sub.11.0.50H.sub.2  C      O = 38.68, H = 3.76,N = 15.92 C = 38.72H = 3.78N = 15.88       2t      ##STR24##       2.5 g(8.83 mmol) 5.0 g(20.3 mmol) 50 mL 5 g25 mLH.sub.2 O 4.0 g(83%)      200-208° C. C.sub.18 H.sub.21 ClN.sub.6 O.sub.12C = 39.39, H =      3.86,N = 15.31 C = 39.43H = 3.86N = 15.30       2u      ##STR25##       2.5 g(8.83 mmol) 5.0 g(21.8 mmol) 50 mL 5 g25 mL H.sub.2 O 3.6 g(77%)      176-181° C.dec. C.sub.19 H.sub.22 ClN.sub.5 O.sub.11.0.25H.sub.2  C      O = 42.55, H = 4.23,N = 13.06 C = 42.54H = 4.18N = 13.04       2v      ##STR26##       2.0 g(7.04 mmol) 4.3 g(21.9 mmol) 40 mL 4.2 g15 mLH.sub.2 O 2.74 g(78%) 1      12-118° C.dec. C.sub.18 H.sub.19 ClN.sub.6 O.sub.9.H.sub.2 OC =      41.83, H = 4.10,N = 16.26 C = 41.60H = 3.98N = 16.20       2w      ##STR27##       2.5 g(8.83 mmol) 5.19 g(26.5 mmol) 50 mL 5 g25 mLH.sub.2 O 3.5 g(79%)      117- 124° C. C.sub.18 H.sub.19 ClN.sub.6 O.sub.9.0.25H.sub.2 OC =      42.95, H = 3.90,N = 16.70 C = 42.84H = 3.92N = 16.63       2x      ##STR28##       2.5 g(8.83 mmol) 5.19 g(26.5 mmol) 50 mL 5 g25 mLH.sub.2 O 3.2 g(73%)      130-135° C. C.sub.18 H.sub.19 ClN.sub.6 O.sub.9.0.50H.sub.2 OC =      42.52, H = 3.97,N = 16.55 C = 42.42H = 3.90N = 16.48       2y      ##STR29##       2.5 g(8.83 mmol) 5 g 40 mL 5 g25 mLH.sub.2       O 900 mg(20%) 157-162° C. C.sub.18 H.sub.22 ClN.sub.5       O.sub.10.0.25Et.sub.2 OC =  43.68, H = 4.73,N = 13.41 C = 43.72H =      4.56N = 13.34       2z      ##STR30##       1.5 g(5.32 mmol) 3 mL 30 mL 3 g15 mLH.sub.2       O 2.25 g(84%) 139-142° C. C.sub.19 H.sub.24 ClN.sub.5       O.sub.9.H.sub.2 OC = 43.89, H = 5.04,N = 13.47 C = 44.00H = 5.02N =      13.38       2aa      ##STR31##       2.5 g(8.83 mmol) 5 g 50 mL 5 g25 mLH.sub.2 O 3.5 g(80%) 154-158°      C. C.sub.19 H.sub.24 ClN.sub.5 O.sub.9.0.625H.sub.2 OC = 44.47, H =      N      4.96,= 13.65 C = 44.46H = 5.11N = 13.74        2bb      ##STR32##       1.5 g(5.32 mmol) 2 mL 30 mL 3 g15 mLH.sub.2       O 1.8 g(67%) 117-123° C. C.sub.19 H.sub.24 ClN.sub.5       O.sub.9.H.sub.2 OC = 43.89, H = 5.04,N = 13.47 C = 43.96H = 5.12N =      13.58       2cc      ##STR33##       2.0 g(7.09 mmol) 3 mL 30 mL 4 g20 mLH.sub.2       O 1.1 g(31%) 120-130° C. C.sub.19 H.sub.24 ClN.sub.5       O.sub.9.0.75H.sub.2 OC = 44.28, H = 4.99,N = 13.59 C = 44.38H = 4.90N =      13.65       2dd      ##STR34##        2.5 g(8.83 mmol) 4.5 g 50 mL 5 g25 mLH.sub.2       O 3.1 g(74%) 150-154° C. C.sub.17 H.sub.20 ClN.sub.5       O.sub.9.H.sub.2 O.0.10Et.sub.2 OC = 41.86, H = 4.64,N = 14.03 C =      42.00H = 4.50N = 14.12       2ee      ##STR35##       2.5 g(8.83 mmol) 5 g 50 mL 5 g25 mLH.sub.2       O 1.75 g(39%) 114-122° C. C.sub.17 H.sub.18 ClF.sub.2 N.sub.5      O.sub.9.H.sub.2 OC = 38.68, H = 3.82,N = 13.27 C = 38.81H = 3.81N =      13.24       2ff      ##STR36##       2.5 g(8.83 mmol) 5 g 50 mL  5 g25 mLH.sub.2       O 2.0 g(44%) 129-134° C. C.sub.17 H.sub.18 ClF.sub.2 N.sub.5      O.sub.9.0.625H.sub.2 OC = 39.18, H = 3.72,N = 13.44 C = 39.22H = 3.74N =      13.36       2gg      ##STR37##       2.5 g(8.83 mmol) 5 g 50 mL 5 g25 mLH.sub.2 O 3.4 g(76%) 108-118°      C. C.sub.17 H.sub.18 ClF.sub.2 N.sub.5 O.sub.9.0.75H.sub.2 OC = 39.02, H      = 3.76,H = 13.38 C = 39.00H = 3.76N =      Ado = adenosine.

EXAMPLE 29 Antiviral Activity of Adenosine-N'-Oxides and Substituted 1-(Benzyloxy)adenosines in Vero cells

Adenosine-N'-oxides and substituted 1-(benzyloxy) adenosines were tested against vaccinia viruses that replicate in mammalian cells growing in cell culture. The results of these tests in Vero cells are summarized in Table 3. The Virus Rating (VR) is a standard weighted measurement of antiviral activity which takes into account the degree of inhibition of virus-induced cytopathogenic effects (CPE) and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of R. W. Sidwell and N. J. Huffman, Appl. Microbiol., 22, 797-801 (1971).

In tests carried out by this method, a greater value of VR indicates greater antiviral activity. A compound with a VR of 1.0 or greater is considered to have significant antiviral activity with a high degree of reproducibility in confirmatory in vitro tests. A compound with a VR of 0.5-0.9 is considered to have possible or marginal activity; a compound with a VR of less than 0.5 is considered to be inactive.

The MIC₅₀ (minimum inhibitory concentration, 50%) is the concentration of a test compound required for 50% inhibition of virus-induced cytopathogenic effect calculated by using a regression analysis program for semilog curve fitting. MTC (minimum toxic concentration) is the minimum drug concentration (μg/ml) causing any cytotoxicity. TI is the therapeutic index, calculated by dividing the minimum cytotoxic drug concentration (MTC) by the minimum inhibitory concentration, 50% (MIC₅₀). The results were compared with the commercial antiviral agent 9-β-D-arabinofuranosyladenine (Ara-A). The tests summarized in Table 3 show that definite antiviral activity against vaccinia virus is exhibited by the compounds tested.

                                      TABLE 3                                      __________________________________________________________________________     Activity vs Vaccinia Virus Substituted-Benzyloxy Derivatives (grouped by       substituents)                                                                   Compd.                                                                              Base                                                                                       ##STR38##  V.sub.r.sup.a                                                                       ID.sub.50.sup.b                                                                     MTC.sup.c                                                                           TI.sup.d                           __________________________________________________________________________     1a   AdoN.sup.1O --         >2.4 0.32  100 312                                 1b   dAdoN.sup.1O                                                                               --         >1.7 3.06 >320 104                                 1c   N.sup.6MeAdoN.sup.1O                                                                       --         >2.4 0.45  320 708                                 2a   AdoN.sup.1O 3-CH.sub.3 >2.4 0.41 >320 781                                                                  0.66      487                                 2b   "           4-CH.sub.3 2.4  0.11  100 917                                 2c   "           2-CH.sub.3 >2.4 0.32 >320 1000                                2d   "           4-OCH.sub.3                                                                               3.3  0.01  100 10000                                                           >3.0        10 1167                                                            2.8         32 2805                                2e   "           3-OCH.sub.3                                                                               >2.8 0.20 >320 1609                                                            >2.6 0.30      1075                                2f   "                      >2.7 <0.32                                                                               >320 1000                                                            >2.4 0.33 >100 306                                 2g   "           2-F        >1.7 4.97 >320  64                                                             >1.5 9.48       34                                 2h   "           3-F        >2.3 0.98 >320 325                                                             >2.2 1.12      285                                 2i   "           4-F        >2.1 2.41 >320 133                                                             >2.0 2.00      160                                 2j   "           2,4-F      >2.4 0.31 >320 1029                                2k   "           3,4-F      >2.3 0.48 >320 671                                                             >2.3 0.74      434                                 2l   "           2-CF.sub.3 >2.2 0.82 >320 391                                 2m   "           3,5-CF.sub.3                                                                              >2.1 1.03 >320 311                                                             >2.0 1.02      314                                 2n   "           2,4-CF.sub.3                                                                              >2.0 1.45 >320 221                                                             >1.9 1.77      181                                 2o   "           2-Cl       >2.2 1.01 >320 318                                                             >1.9 1.27      251                                 2p   "           3-Cl       >2.0 1.08 >320 295                                                             >1.9 1.66      193                                 2q   "           2-NO.sub.2 >2.1 1.03 >320 310                                                             >1.9 1.77      181                                 2r   "           3-NO.sub.2 >1.2 10.0 >320  32                                                             >1.1 10.7       30                                 2s   "           4-NO.sub.2 >1.7 2.34 >320 137                                                             >1.7 3.59       89                                 2t   "           2-OCH.sub.3                                                                               >2.0 2.01 >320 160                                                  5-NO.sub.2 >1.6 3.68       87                                 2u   "           3-COOCH.sub.3                                                                             >2.0 1.55 >320 207                                                             >1.8 2.30      139                                 2v   "           4-CN       >1.8 3.20 >320 100                                                             >1.7 2.40      134                                 2w   "           2-CN       >2.0 1.55 >320 207                                                             >1.4 6.37       50                                 2x   "           3-CN       >2.0 0.76 >320 182                                                             >1.8 2.39      134                                 2y   AdoN.sup.1O 2-OCH.sub.3                                                                               2.7  0.17  320 1935                                                            >3.1 0.11      >3020                               2z   "           3,4-CH.sub.3                                                                              >2.6 0.32  320 >1000                                                           >2.8 0.18      >1760                               2aa  "           3,5-CH.sub.3                                                                              >2.5 0.45  320 710                                                             >2.6 0.32      >1000                               2bb  "           2,5-CH.sub.3                                                                              >2.6 0.38  320 >850                                                            >2.8 0.24      >1350                               2cc  "           2,4-CH.sub.3                                                                              2.9  0.08  320 4110                                                            2.9  0.08      3890                                2dd  "           H          >2.0 1.77  320 180                                                             >2.0 1.77      180                                 2ff  "           2,6-F      >2.0 1.55  320 205                                                             >2.0 1.83      175                                 2gg  "           2,5-F      >2.0 1.77  320 180                                                             >1.9 2.79      115                                 Control                                                                             AraA        --         1.0  2.00 >320   13.3                              __________________________________________________________________________      +HU a VR  Virus rating calculated by the method of R. W. Sidwell and J. N      Huffman, Appl. Microbiol., 22, 797-801 (1971).                                 .sup.b ID.sub.50 - Inhibitory dose 50. Concentration of the drug that          causes a 50% reduction in virus replication.                                   .sup.c MTC  Minimum toxic concentration. The lowest concentration of the       test compound that results in a 50% reduction in the percent survival of       viable host cells.                                                             .sup.d TI  Therapeutic index. A measure of the antiviral potential for th      drug calculated as MTC/ID.sub.50. TI>50 indicates a useful compound.     

EXAMPLE 30 Activity of Adenosine-N'-Oxides and Substituted 1-(Benzyloxy)adenosines in Vivo

The in vivo model used in these studies was originally developed by Boyle et al (Antimicrob. Agents Chemother., 1966, 1967, 536) and further defined by Joshi et al (Appl. Microbiol. 1969, 18, 935). Mice inoculated in the tail vein with vaccinia virus develop dermal lesions over the entire tail surface. These lesions, enumerated after fluorescence staining, are a function of the virus challenge level, animal weight and inoculation distance from the base of the tail. The IHD strain of vaccinia virus, passaged once in mouse brain and once in primary rabbit kidney cell culture, was used. Outbred Swiss mice (CD-1, VAF+, Charles River Laboratories, Inc ), weighing 18-21 g, were inoculated with 0.2 ml of a 1:40 dilution of the stock virus via the tail vein (1 cm from the base). Test compounds were administered intraperitoneally once daily for seven days, with the first dose given the day preceding virus challenge. Each treatment group was composed of 20 virus-infected mice. Uninfected, drug-treated toxicity controls (5 mice per group) were included for each treatment administered. The positive control compound, which was included in all assays, was ara-A. Diluent control mice received inoculations with the appropriate compound diluent on the same schedule as the compound treated mice. Animals were sacrificed on the sixth day and their tails were stained with a solution of 1% fluorescein-0.5% methylene blue in 70% methanol. Lesions were enumerated under UV light (254 nm) with the aid of a hand lens. The mean and medium number of lesions for each treatment group were calculated prior to, and following square root transformation of the individual tailpox counts. Tailpox counts from each of the treatment groups were compared by Student's t test.

Comparison of test compounds with untreated controls is shown in Table 4. A greater figure for ##EQU1## indicates greater antiviral activity.

                  TABLE 4                                                          ______________________________________                                         In Vivo Activity vs. Vaccinia Virus                                            Mouse Tail Pox Model (IP Drug)                                                  ##STR39##                                                                      poundCom-                                                                            R                                                                                              ##STR40##                                               ______________________________________                                         2c                                                                                    ##STR41##      50                                                       2i                                                                                    ##STR42##      31                                                       2aa                                                                                   ##STR43##      57                                                       2b                                                                                    ##STR44##      39                                                       2a                                                                                    ##STR45##      54                                                       2l                                                                                    ##STR46##      39                                                       --    AraA            53                                                       1a    Parent N-oxide  44                                                       ______________________________________                                     

What is claimed is:
 1. A compound of the formula ##STR47## where X is perchlorate, hydrogen or fluoroborate,R is hydrogen or methyl R¹ is ribosyl or 2'-deoxyribosyl, and R² is a member selected from the group consisting of the following substituted arylalkyl groups: ##STR48##
 2. The compound of claim 1 wherein R¹ is ribosyl.
 3. The compound of claim 1 wherein X is perchlorate.
 4. The compound of claim 1 wherein R is hydrogen.
 5. The compound of claim 1 that is 1-(4-methoxybenzyloxy)adenosine, perchloric acid salt.
 6. The compound of claim 1 that is 1-(3-methoxybenzyloxy)adenosine, perchloric acid salt.
 7. The compound of claim 1 that is 1-(1-phenylethyloxy)adenosine, perchloric acid salt.
 8. The compound of claim 1 that is 1-(2-fluorobenzyloxy)adenosine, perchloric acid salt.
 9. The compound of claim 1 that is 1-(2,4-difluorobenzyloxy)adenosine, perchloric acid salt.
 10. The compound of claim 1 that is 1-(3,4-difluorobenzyloxy)adenosine, perchloric acid salt.
 11. The compound of claim 1 that is 1-(2-trifluoromethylbenzyloxy)adenosine, perchloric acid salt.
 12. The compound of claim 1 that is 1-[3,5-bis(trifluoromethyl)benzyloxy]adenosine, perchloric acid salt.
 13. The compound of claim 1 that is 1-[2,4-bis(trifluoromethyl)benzyloxy]adenosine, perchloric acid salt.
 14. The compound of claim 1 that is 1-(2-chlorobenzyloxy)adenosine, perchloric acid salt.
 15. The compound of claim 1 that is 1-(3-chlorobenzyloxy)adenosine, perchloric acid salt.
 16. The compound of claim 1 that is 1-(2-nitrobenzyloxy)adenosine, perchloric acid salt.
 17. The compound of claim 1 that is 1-(3-nitrobenzyloxy)adenosine, perchloric acid salt.
 18. The compound of claim 1 that is 1-(2-methoxy-5-nitrobenzyloxy)adenosine, perchloric acid salt.
 19. The compound of claim 1 that is 1-(3-methoxycarbonylbenzyloxy)adenosine, perchloric acid salt.
 20. The compound of claim 1 that is 1-(4-cyanobenzyloxy)adenosine, perchloric acid salt.
 21. The compound of claim 1 that is 1-(2-cyanobenzyloxy)adenosine, perchloric acid salt.
 22. The compound of claim 1 that is 1-(3-cyanobenzyloxy)adenosine, perchloric acid salt.
 23. The compound of claim 1 that is 1-(2-methoxybenzyloxy)adenosine, perchloric acid salt.
 24. The compound of claim 1 that is 1-(3,4-dimethylbenzyloxy)adenosine, perchloric acid salt.
 25. The compound of claim 1 that is 1-(3,5-dimethylbenzyloxy)adenosine, perchloric acid salt.
 26. The compound of claim 1 that is 1-(2,5-dimethylbenzyloxy)adenosine, perchloric acid salt.
 27. The compound of claim 1 that is 1-(2,4-dimethylbenzyloxy)adenosine, perchloric acid salt.
 28. The compound of claim 1 that is 1-benzyloxyadenosine, perchloric acid salt.
 29. The compound of claim 1 that is 1-(2,6-difluorobenzyloxy)adenosine, perchloric acid salt.
 30. The compound of claim 1 that is 1-(3,5-difluorobenzyloxy)adenosine, perchloric acid salt.
 31. The compound of claim 1 that is 1-(2,5-difluorobenzyloxy)adenosine, perchloric acid salt.
 32. A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier for oral, topical or parenteral administration to mamal.
 33. A method for preventing vaccinia viral infection in an animal receiving an administration of a vaccinia virus used as a vector, which method comprises administering to an animal in need thereof a prophylactically effective amount of a compound of claim
 1. 34. A method for preventing vaccinia viral infection in an animal receiving an administration of a vaccinia virus used as a vector, which method comprises administering to an animal in need thereof a prophylactically effective amount of a compound of claim
 2. 35. A method for preventing vaccinia viral infection in an animal receiving an administration of a vaccinia virus used as a vector, which method comprises administering to an animal in need thereof a prophylactically effective amount of a compound of claim
 3. 36. A method for preventing vaccinia viral infection in an animal receiving an administration of a vaccinia virus used as a vector, which method comprises administering to an animal in need thereof a prophylactically effective amount of a compound of claim
 4. 37. A method for preventing vaccinia viral infection in an animal receiving an administration of a vaccinia virus used as a vector, which method comprises administering to an animal in need thereof a prophylactically effective amount of a compound selected from the group of the following adenosine N¹ oxides and substituted 1-(benzyloxy) adenosines: ##STR49## where R is hydrogen or methyl, and R¹ is ribosyl or 2'-deoxyribosyl, and ##STR50## where X, R, R¹, and R² are as defined in claim
 1. 38. A method for the treatment of a host animal having a vaccinia virus infection which comprises administering to said host animal a therapeutically effective amount of a compound selected from the group of the following adenosine N¹ oxides and substituted 1-(benzyloxy) adenosines: ##STR51## where R is hydrogen or methyl, and R¹ is ribosyl or 2'-deoxyribosyl, and ##STR52## where X, R, R¹, and R² are as defined in claim
 1. 39. A method for the treatment of a host animal having a vaccinia virus infection which comprises administering to said host animal a therapeutically effective amount of a compound of the formula ##STR53## where X is perchlorate, hydrogen, or fluoroborate,R is hydrogen or methyl R¹ is ribosyl or 2'-deoxyribosyl, and R² is a member selected from the group consisting of the following substituted arylalkyl groups: ##STR54##
 40. The method of claim 39 wherein R¹ is ribosyl.
 41. The method of claim 39 wherein X is perchlorate.
 42. The method of claim 39 wherein H is hydrogen. 